Pharmacytimes http://www.pharmacytimes.com/rss PharmacyTimes.com offers continuing education (CE) courses, career guidance for pharmacy students, online-only articles, digital versions of the print issue, and more, that are essential to pharmacists en-us Tue, 25 Jun 19 09:36:34 +0000 Tue, 25 Jun 19 09:36:34 +0000 Retail Pharmacy Provides More Drug Disposal Options http://www.pharmacytimes.com/news/walgreens-rolls-out-new-drug-disposal-options http://www.pharmacytimes.com/news/walgreens-rolls-out-new-drug-disposal-options In an effort to combat the opioid epidemic, Walgreens has introduced its recently announced an addition to its drug disposal program in the form of DisposeRx packets. Mon, 24 Jun 19 14:00:00 +0000 Tezacaftor/Ivacaftor Receives FDA Approval for Patients Ages 6 and Older with Cystic Fibrosis http://www.pharmacytimes.com/news/tezacaftorivacaftor-receives-fda-approval-for-patients-ages-6-and-older-with-cystic-fibrosis http://www.pharmacytimes.com/news/tezacaftorivacaftor-receives-fda-approval-for-patients-ages-6-and-older-with-cystic-fibrosis This approval expands tezacaftor/ivacaftor&rsquo;s indication to include patients ages 6 and older with cystic fibrosis who have certain genetic mutations.<br /> &nbsp; Fri, 21 Jun 19 18:48:00 +0000 FDA Addresses Benefit-Risk Framework for Evaluating Opioid Analgesics http://www.pharmacytimes.com/news/fda-addresses-benefitrisk-framework-for-evaluating-opioid-analgesics http://www.pharmacytimes.com/news/fda-addresses-benefitrisk-framework-for-evaluating-opioid-analgesics The goal, according to agency officials, is to ensure product approval and removal decisions are science-based and that the agency&rsquo;s benefit-risk framework considers not only the outcomes of prescription opioids when used as prescribed, but also the public health effects of inappropriate use. Thu, 20 Jun 19 18:22:00 +0000 First Small Cell Lung Cancer Indication for Pembrolizumab Granted FDA Approval http://www.pharmacytimes.com/news/first-small-cell-lung-cancer-indication-for-pembrolizumab-granted-fda-approval http://www.pharmacytimes.com/news/first-small-cell-lung-cancer-indication-for-pembrolizumab-granted-fda-approval Pembrolizumab is already an established treatment option for non-small cell lung cancer, with several approved indications for its use in the disease. Tue, 18 Jun 19 14:22:00 +0000 FDA OKs Fifth Biosimilar to Trastuzumab http://www.pharmacytimes.com/news/fda-oks-fifth-biosimilar-to-trastuzumab http://www.pharmacytimes.com/news/fda-oks-fifth-biosimilar-to-trastuzumab Officials with the FDA approved Amgen&rsquo;s trastuzumab-anns, also known as ABP 980 (Kanjinti), the fifth FDA-approved biosimilar referencing trastuzumab (Herceptin).<br /> &nbsp; Thu, 13 Jun 19 20:10:00 +0000 Risk of Pediatric Shingles Reduced by Varicella Vaccine, Study Finds http://www.pharmacytimes.com/news/risk-of-pediatric-shingles-reduced-by-varicella-vaccine-study-finds- http://www.pharmacytimes.com/news/risk-of-pediatric-shingles-reduced-by-varicella-vaccine-study-finds- A new study finds duel benefit of the varicella vaccine Wed, 12 Jun 19 16:01:00 +0000 Vitamin K Helps, Not Harms Patients on Warfarin http://www.pharmacytimes.com/news/vitamin-k-helps-not-harms-patients-on-warfarin http://www.pharmacytimes.com/news/vitamin-k-helps-not-harms-patients-on-warfarin The trial analyzed the impact of vitamin K intake on patients who were taking warfarin to decrease the risk of blood clots. Wed, 12 Jun 19 13:05:00 +0000 FDA Approval: Polivy for Relapsed, Refractory Diffuse Large B-Cell Lymphoma http://www.pharmacytimes.com/news/fda-approves-polivy-for-relapsed-refractory-diffuse-large-bcell-lymphoma http://www.pharmacytimes.com/news/fda-approves-polivy-for-relapsed-refractory-diffuse-large-bcell-lymphoma Tue, 11 Jun 19 16:40:00 +0000 Neostigmine Methylsulfate Injection Ready-to-Fill Syringes Launched http://www.pharmacytimes.com/news/neostigmine-methylsulfate-injection-readytofill-syringes-launched http://www.pharmacytimes.com/news/neostigmine-methylsulfate-injection-readytofill-syringes-launched The Neostigmine Methylsulfate Injection is the first manufacturer-prepared, ready-to-administer prefilled syringe on the market. Mon, 10 Jun 19 20:09:00 +0000 New Program Provides Emergency Medicine Certificate to Pharmacists http://www.pharmacytimes.com/news/new-program-provides-emergency-medicine-certificate-to-pharmacists http://www.pharmacytimes.com/news/new-program-provides-emergency-medicine-certificate-to-pharmacists This course focuses on the application of evidence-based pharmacologic and nonpharmacologic therapies for clinical scenarios frequently encountered in the emergency department. Thu, 06 Jun 19 17:28:00 +0000 Generic Treatment for Parkinson Disease Receives FDA Approval http://www.pharmacytimes.com/news/generic-treatment-for-parkinson-disease-receives-fda-approval http://www.pharmacytimes.com/news/generic-treatment-for-parkinson-disease-receives-fda-approval The drug is therapeutically equivalent to Merck&rsquo;s Sinemet CR Tablets, 25 mg/100 mg and 50 mg/200 mg. Thu, 06 Jun 19 17:00:00 +0000 Survey Finds Perception Among Challenges in Combating Drug Diversion in Hospitals http://www.pharmacytimes.com/news/survey-finds-perception-among-challenges-in-combating-drug-diversion-in-hospitals http://www.pharmacytimes.com/news/survey-finds-perception-among-challenges-in-combating-drug-diversion-in-hospitals Overall, 85% of those surveyed were concerned about this problem in the United States, while 20% think that there is a problem in their own workplaces. Wed, 05 Jun 19 16:57:00 +0000 Pharmacists First to Receive New Practitioner Leadership Development Research Grant http://www.pharmacytimes.com/news/pharmacists-first-to-receive-new-practitioner-leadership-development-research-grant- http://www.pharmacytimes.com/news/pharmacists-first-to-receive-new-practitioner-leadership-development-research-grant- The new grant was created to stimulate innovative leadership development practices that enhance outcomes for clinicians, patients, and organizations. Tue, 04 Jun 19 17:25:00 +0000 Pembrolizumab Demonstrates Improved Overall Survival as Initial Treatment of Recurrent or Metastatic HNSCC http://www.pharmacytimes.com/news/pembrolizumab-demonstrates-improved-overall-survival-as-initial-treatment-of-recurrent-or-metastatic-hnscc http://www.pharmacytimes.com/news/pembrolizumab-demonstrates-improved-overall-survival-as-initial-treatment-of-recurrent-or-metastatic-hnscc Although recent trials for Merck&#39;s&nbsp;pembrolizumab injection demonstrated promise for recurrent or metastatic head and neck squamous cell carcinoma, testing for patients with metastatic triple-negative breast cancer did not meet the primary endpoint. Fri, 31 May 19 19:32:00 +0000 FDA Seeks Feedback on Potential Special Packaging Requirement for Certain Opioid Medications http://www.pharmacytimes.com/news/fda-seeks-feedback-on-potential-special-packaging-requirement-for-certain-opioid-medications http://www.pharmacytimes.com/news/fda-seeks-feedback-on-potential-special-packaging-requirement-for-certain-opioid-medications The agency has opened a public docket to solicit feedback on the proposed requirement, which would necessitate certain immediate-release opioid analgesics be made available in fixed-quantity, unite-of-use blister packaging. &nbsp; Thu, 30 May 19 20:42:00 +0000 FDA Approves Addition of Overall Survival Data in Giliterinib Labeling for AML http://www.pharmacytimes.com/news/fda-approves-addition-of-overall-survival-data-in-giliterinib-labeling-for-aml http://www.pharmacytimes.com/news/fda-approves-addition-of-overall-survival-data-in-giliterinib-labeling-for-aml Gilteritinib (Xospata, Astellas Pharma) is indicated for adults with relapsed/refractory acute myeloid leukemia with an FMS-like tyrosine kinase 3 mutation. Thu, 30 May 19 14:45:00 +0000 Nutrition Support Certificate Program Launched for Pharmacists and Other Health Care Providers http://www.pharmacytimes.com/news/nutrition-support-certificate-program-launched-for-pharmacists-and-other-health-care-providers http://www.pharmacytimes.com/news/nutrition-support-certificate-program-launched-for-pharmacists-and-other-health-care-providers The online program trains health care professionals in fundamentals of enteral and parenteral nutrition.&nbsp; Wed, 29 May 19 14:45:00 +0000 Lenalidomide, Rituximab Combo Granted FDA Approval for Indolent Non-Hodgkin Lymphoma http://www.pharmacytimes.com/news/lenalidomide-rituximab-combo-granted-fda-approval-for-indolent-nonhodgkin-lymphoma http://www.pharmacytimes.com/news/lenalidomide-rituximab-combo-granted-fda-approval-for-indolent-nonhodgkin-lymphoma The approval of R2&nbsp;is based on data from the phase 3 AUGMENT study evaluating the safety and efficacy of the combination regimen compared with rituximab plus placebo in patients with previously-treated FL and MZL.&nbsp; Tue, 28 May 19 18:28:00 +0000 FDA Approves Treatment for Patients with Acute Graft-Versus-Host Disease http://www.pharmacytimes.com/news/fda-approves-treatment-for-patients-with-acute-graftversushost-disease http://www.pharmacytimes.com/news/fda-approves-treatment-for-patients-with-acute-graftversushost-disease Ruxolitinib is the first and only&nbsp;FDA-approved treatment for this indication, according to Incyte, the drug&#39;s manufacturer. Fri, 24 May 19 20:14:00 +0000 New Therapy for Breast Cancer Granted FDA Approval http://www.pharmacytimes.com/news/new-therapy-for-breast-cancer-granted-fda-approval http://www.pharmacytimes.com/news/new-therapy-for-breast-cancer-granted-fda-approval Officials with the FDA have approved alpelisib (Piqray, Novartis) tablets, to be used in combination with the endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, <em>PIK3CA</em>-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. Fri, 24 May 19 19:00:00 +0000 FDA OKs Gene Therapy for Children with Spinal Muscular Atrophy http://www.pharmacytimes.com/news/fda-oks-gene-therapy-for-children-with-spinal-muscular-atrophy http://www.pharmacytimes.com/news/fda-oks-gene-therapy-for-children-with-spinal-muscular-atrophy The drug, onasemnogene abeparvovec-xioi (Zolgensma, AveXis), is an adeno-associated virus vector-based gene therapy that targets the cause of SMA, a leading genetic cause of infant mortality. Fri, 24 May 19 17:42:00 +0000 Treatment for Plaque Psoriasis in Adolescent Patients Granted FDA Approval http://www.pharmacytimes.com/news/treatment-for-plaque-psoriasis-in-adolescent-patients-granted-fda-approval http://www.pharmacytimes.com/news/treatment-for-plaque-psoriasis-in-adolescent-patients-granted-fda-approval Calcipotriene foam was approved by the FDA in 2010 for patients age 18 years and older. Thu, 23 May 19 10:00:00 +0000 FDA Officials OK New Octaplas Product Label http://www.pharmacytimes.com/news/fda-officials-ok-new-octaplas-product-label http://www.pharmacytimes.com/news/fda-officials-ok-new-octaplas-product-label Results of study demonstrate safety profile in pediatric patients.&nbsp; Wed, 22 May 19 17:04:00 +0000 Cancer Medication Developer to be Acquired by Merck http://www.pharmacytimes.com/news/cancer-medication-developer-to-be-acquired-by-merck http://www.pharmacytimes.com/news/cancer-medication-developer-to-be-acquired-by-merck The acquisition agreement with Peloton includes the drug candidate PT2977, a novel oral HIF-2&alpha; inhibitor in late-stage development for renal cell carcinoma (RCC). Tue, 21 May 19 16:28:00 +0000 FDA Approves Generic Treatments for Overactive Bladder http://www.pharmacytimes.com/news/fda-approves-generic-treatments-for-overactive-bladder http://www.pharmacytimes.com/news/fda-approves-generic-treatments-for-overactive-bladder Solifenacin succinate tablet is a muscarinic antagonist indicated to treat this condition, with symptoms of urgency, urge urinary incontinence, and urinary frequency. Tue, 21 May 19 13:22:00 +0000